Accord Logo

Intended for UK patients and members of the public

SmPC - Reltebon 20mg Prolonged-release Tablets: Change history

  • C.I.2.a: SmPC section 4.8 has been updated in line with the reference product OxyContin 5mg prolonged release tablets (PL 16950/0123; MAH: Napp Pharmaceuticals Ltd) dated 27th June 2024.

    C.I.3.a: SmPC section 4.4 and the PIL have been updated in line with the PRAC recommendation PSUSA/00002254/202404.

    SmPC sections updated: 4.4, 4.8, 4.9 and 10.

    • Changes: (Updated: 14 Mar 2025)

      C.I.2.a: SmPC section 4.8 has been updated in line with the reference product OxyContin 5mg prolonged release tablets (PL 16950/0123; MAH: Napp Pharmaceuticals Ltd) dated 27th June 2024.

      C.I.3.a: SmPC section 4.4 and the PIL have been updated in line with the PRAC recommendation PSUSA/00002254/202404.

      SmPC sections updated: 4.4, 4.8, 4.9 and 10.

    • Changes: (Updated: 04 Mar 2025)

      IAIN C.I.3.a. MHRA request to include OIVI & PPOU in SmPC section 4.4 and PIL.

      SmPC sections updated: 4.4 & 10.

    • Changes: (Updated: 25 Sep 2024)

      Child-resistant blister pack (PVC/PVdC/Al/PET/paper) removed from SmPC 6.5.

    • Changes: (Updated: 08 Apr 2024)

      Description of update: To update sections 4.4 and 4.8 of the SPC, and sections 2 and 4 of the PIL to bring in line with PSUSA/00002254/202304 for Oxycodone and risk of SOD. In addition, editorial updates have been made to the PIL.

      SmPC Sections updated: 4.4, 4.8 and 10.

    • Changes: (Updated: 18 May 2023)

      Variation Description: SmPC sections 4.2, 4.4, 4.8, 4.9 and the PIL have been updated in line with the PRAC recommendation (PSUSA/00002254/202204) regarding opioid use disorder. PIL section 6 has also been updated to reword the section “What Reltebon looks like and contents of the pack”.

      SmPC sections updated – 4.2, 4.4, 4.8, 4.9 and 10.

    • Changes: (Updated: 21 Sep 2022)

      Initial upload

    View product information as a: